FY2025 Earnings Estimate for uniQure Issued By HC Wainwright

uniQure (NASDAQ:QURE) – Research analysts at HC Wainwright lifted their FY2025 EPS estimates for shares of uniQure in a report issued on Tuesday, March 4th. HC Wainwright analyst P. Trucchio now forecasts that the biotechnology company will earn ($2.93) per share for the year, up from their prior estimate of ($2.99). HC Wainwright has a “Buy” rating and a $70.00 price target on the stock. The consensus estimate for uniQure’s current full-year earnings is ($3.75) per share. HC Wainwright also issued estimates for uniQure’s Q4 2025 earnings at ($0.81) EPS, FY2026 earnings at ($1.92) EPS, FY2027 earnings at $7.95 EPS, FY2028 earnings at $18.09 EPS and FY2029 earnings at $19.96 EPS.

Several other analysts also recently issued reports on the stock. Cantor Fitzgerald increased their price objective on shares of uniQure from $28.00 to $58.00 and gave the company an “overweight” rating in a research report on Tuesday, December 10th. The Goldman Sachs Group increased their price objective on shares of uniQure from $9.00 to $20.00 and gave the company a “neutral” rating in a research report on Thursday, December 12th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $24.00 price objective on shares of uniQure in a research report on Tuesday, January 21st. Mizuho increased their price objective on shares of uniQure from $7.00 to $20.00 and gave the company a “neutral” rating in a research report on Thursday, December 19th. Finally, Stifel Nicolaus increased their price objective on shares of uniQure from $12.00 to $32.00 and gave the company a “buy” rating in a research report on Monday, December 16th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $38.89.

uniQure Stock Down 2.2 %

Shares of NASDAQ:QURE opened at $12.23 on Friday. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. uniQure has a 52-week low of $3.73 and a 52-week high of $19.18. The company has a 50 day moving average of $14.48 and a two-hundred day moving average of $9.96. The company has a market capitalization of $596.13 million, a price-to-earnings ratio of -2.47 and a beta of 0.38.

Hedge Funds Weigh In On uniQure

Institutional investors and hedge funds have recently bought and sold shares of the business. Avoro Capital Advisors LLC acquired a new stake in shares of uniQure during the fourth quarter worth approximately $38,410,000. Franklin Resources Inc. purchased a new stake in uniQure in the 3rd quarter worth approximately $7,360,000. RTW Investments LP boosted its stake in shares of uniQure by 8,936.3% during the 4th quarter. RTW Investments LP now owns 903,625 shares of the biotechnology company’s stock valued at $15,958,000 after buying an additional 893,625 shares during the period. Point72 Asset Management L.P. grew its holdings in shares of uniQure by 81.3% during the 4th quarter. Point72 Asset Management L.P. now owns 1,771,352 shares of the biotechnology company’s stock valued at $31,282,000 after acquiring an additional 794,459 shares in the last quarter. Finally, Boxer Capital Management LLC acquired a new position in shares of uniQure in the fourth quarter worth $13,245,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

Insider Transactions at uniQure

In other news, CFO Christian Klemt sold 14,341 shares of uniQure stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $10.70, for a total transaction of $153,448.70. Following the transaction, the chief financial officer now owns 152,372 shares in the company, valued at approximately $1,630,380.40. The trade was a 8.60 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Matthew C. Kapusta sold 26,727 shares of the stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $10.70, for a total value of $285,978.90. Following the completion of the sale, the chief executive officer now directly owns 571,188 shares of the company’s stock, valued at approximately $6,111,711.60. This represents a 4.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 96,044 shares of company stock valued at $1,001,040. 4.74% of the stock is currently owned by corporate insiders.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.